What question did this study set out to answer?

To review the mechanisms of cardiotoxicity caused by common anticancer agents and radiation therapy, while detailing surveillance strategies and clinical management.

June 29, 2017Future Cardiology

Cardio-oncology: Cardiovascular Complications of Cancer Therapy

View Full Paper

Ask AI

Bookmark

Why the study?

What are the cardiovascular complications of cancer therapy and how should they be monitored and managed?

Population

Patients receiving cancer therapy (anthracyclines, trastuzumab, tyrosine kinase inhibitors, radiation therapy)

Design

Review

Authors

RHRobert J. HenningLouisiana State University Health Sciences Center Shreveport RHRaymond D. HarbisonUniversity of South Florida

Discussion

Member takes

Implication

Alerts clinicians to cardiotoxicity mechanisms in cancer therapy; leaves open optimal prevention and monitoring strategies.

Key Points

To review the mechanisms of cardiotoxicity caused by common anticancer agents and radiation therapy, while detailing surveillance strategies and clinical management.
Synthesized evidence evaluating the cardiotoxic profiles of anthracyclines, trastuzumab, and tyrosine kinase inhibitors alongside mediastinal radiation.
Evaluated the diagnostic sensitivity of left ventricular ejection fraction compared with echocardiographic global longitudinal strain for detecting myocardial injury.
Anthracyclines induce cardiomyocyte necrosis and fibrosis, trastuzumab causes cardiac stunning, and tyrosine kinase inhibitors elevate arterial pressure and impair contractility.
Thoracic radiation exacerbates drug-induced cardiotoxicity and promotes accelerated atherosclerosis, myocardial infarction, arrhythmias, and heart failure.
Echocardiographic measurement of global longitudinal strain detects early left ventricular systolic dysfunction with greater sensitivity than traditional left ventricular ejection fraction.

Structured PICO

What are the cardiovascular complications of cancer therapy and how should they be monitored and managed?

Population

Patients receiving cancer therapy (anthracyclines, trastuzumab, tyrosine kinase inhibitors, radiation therapy)

Intervention

Cancer therapies (anthracyclines, trastuzumab, tyrosine kinase inhibitors, radiation therapy)

Outcome

Cardiotoxicity (cardiomyocyte necrosis, fibrosis, cardiac stunning, increased systemic arterial pressure, impaired myocyte contractility, accelerated atherosclerosis, myocardial infarction, heart failure, arrhythmias)safety

This review highlights the mechanisms of cardiotoxicity from common cancer therapies and emphasizes the use of global longitudinal strain for early detection of left ventricular systolic dysfunction.

Cite This Study

Henning et al. (2017) studied this question.

synapsesocial.com/papers/6a702b2ea7fbea1e4407f6c3 https://doi.org/10.2217/fca-2016-0081

Topics

Cardio-oncology

View Full Paper

Ask AI

Bookmark

Cardio-oncology: Cardiovascular Complications of Cancer Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Cardio-oncology: Cardiovascular Complications of Cancer Therapy

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider